An observational study in Micropulse Laser, Treatment and Initial, sponsored by The General Authority for Teaching Hospitals and Institutes. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.
Sponsored by The General Authority for Teaching Hospitals and Institutes · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Macular Edema with a site in Egypt — 5 open to participants now, 5 under way, none of them phase 3. Macular Edema · Egypt.
Among the 22 studies in Macular Edema with a site in Egypt, this one is one of 3 that started in 2025, is one of 5 observational ones, and was the 20th registered.
759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.
Browse Macular Edema studies →5 of the 22 studies in Macular Edema with a site in Egypt are open now. Recruiting first, the newest first:
Khadija Ahmed Mhrose Glal · Sites in Egypt
Ages 19–69
Ain Shams University · Sites in Egypt
Ages 18+
Sohag University · Sites in Egypt
Ages 35–65
Tanta University · Sites in Egypt
Healthy volunteers
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 2 · Phase 4 6
First in 2010; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 71 across 127 observational studies indexed under Macular Edema.
Median enrollment 50 across the 17 interventional studies, 52 across the 5 observational. Of the 12 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 22 have an industry lead sponsor. The 10 most frequent:
The General Authority for Teaching Hospitals and Institutes is the lead sponsor of 8 studies on the registry; 6 are open to participants now.
The General Authority for Teaching Hospitals and Institutes has 1 study filed under Macular Edema — fewer than ten, so there is no comparison to draw.
1 of the studies in Macular Edema with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07917338Khadija Ahmed Mhrose GlalOral N-Acetylcysteine on Diabetic Macular Edema | 2027-10-01 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Macular Edema with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the effect of subthreshold 577 nm micropulse laser photocoagulation in the treatment of initial and refractory cases of Center-Involved Diabetic Macular Edema.
Diabetic Retinopathy (DR) is a common and specific microvascular complication of diabetes that affects 17-54% of people with diabetes aged between 49 and 60 years.
Diabetic macular edema (DME) is one of the most common causes of visual loss in today's society. It affects about 10% of diabetic individuals and 29% of those who have had the condition for more than 20 years.
In micropulse mode, the laser emits short pulses, thereby reducing thermal energy in the target area.
This strategy has two properties: a shorter exposure time and a subvisible clinical endpoint, delivering energy by dividing the beam into a series of short pulses (100-300 µs). Every single pulse has an "on and off" duration (duty cycle (DC)), enabling tissues to cool down before the next pulse.
This prospective cohort comparative study was conducted at the Ophthalmology Department of Sohag Teaching Hospital, with approval from the institutional ethical committee.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with treatment-naïve center-involved diabetic macular edema.
Other: Micropulse Laser
Patients with refractory center-involved diabetic macular edema.
Other: Micropulse Laser
All laser procedures will be performed in a darkened room. The laser will be delivered together in an 8×8 pattern mode with high density (0µm of spacing) over the entire area of macular edema, including the foveal center and unthickened (200µm) retina with no attempt to target or avoid microaneurysms.
Change of best-corrected visual acuity
Change of best-corrected visual acuity will be recorded.
Time frame: 6 months post-procedure
Change of central macular thickness
Change of central macular thickness will be recorded.
Time frame: 6 months post-procedure
Change of area thickness
Change of area thickness will be recorded.
Time frame: 6 months post-procedure
Change of macular volume
Change of macular volume will be recorded.
Time frame: 6 months post-procedure
Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Supporting information: Study protocol
Time frame: After the end of study for one year.
Access criteria: The data will be available upon a reasonable request from the corresponding author.
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Mar 2026, 5 months after the start.
Of 44 observational studies under Macular Edema, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 52. This study's planned 5 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The General Authority for Teaching Hospitals and Institutes